Overview

Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

Status:
Recruiting

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

In this study, participants with different types of advanced solid tumors who failed standard treatments will be treated with XNW5004 in combination with KEYTRUDA® (pembrolizumab) .

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Evopoint Biosciences Inc.

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab